Publication: The role of adenosine A1 receptors in the nucleus accumbens during morphine withdrawal
| dc.contributor.coauthor | Jafarova Demirkapu, Mahluga | |
| dc.contributor.coauthor | Yananlı, Hasan Raci | |
| dc.contributor.coauthor | Kaleli, Melisa | |
| dc.contributor.coauthor | Sakallı, Halil Eren | |
| dc.contributor.coauthor | Gören, Mehmet Zafer | |
| dc.contributor.department | School of Medicine | |
| dc.contributor.facultymember | No | |
| dc.contributor.kuauthor | Topkara, Betilay | |
| dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
| dc.date.accessioned | 2024-11-09T23:43:42Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Opioids are effective analgaesic agents, but serious adverse effects such as tolerance and withdrawal contribute to opioid dependence and limit their use. Opioid withdrawal is a common occurrence in human opiate addicts that is not life-threatening. Studies have shown that the mesocorticolimbic system, especially the nucleus accumbens, is an important region in drug addiction and adenosine receptors play a modulatory role in the mechanism of action of drug dependence and withdrawal. The aim of this study was to investigate the effects of the selective A1 receptor agonist CPA (N6-cyclopentyladenosine) on withdrawal symptoms, and the concentration of dopamine and noradrenaline in the nucleus accumbens and locomotor activity behaviour during naloxone-precipitated withdrawal in morphine-dependent rats. The local administration of CPA (1.5, 3.0, and 6.0 mmol/L bilateral 250 nL) into the nucleus accumbens decreased the Gellert–Holtzman withdrawal scale, and increased concentrations of dopamine and noradrenaline in the same region during naloxone-induced withdrawal. Our findings suggest that administration of the A1 receptor agonist significantly decreased withdrawal behaviours and increased dopamine and noradrenaline concentrations in opioid withdrawal in a dose-dependent manner. These results demonstrate that adenosine receptors should be examined as a potential mechanism that could be exploited for the treatment of morphine withdrawal. | |
| dc.description.fulltext | No | |
| dc.description.harvestedfrom | Manual | |
| dc.description.indexedby | WOS | |
| dc.description.indexedby | Scopus | |
| dc.description.indexedby | PubMed | |
| dc.description.openaccess | NO | |
| dc.description.peerreviewstatus | Peer-Reviewed | |
| dc.description.publisherscope | International | |
| dc.description.readpublish | N/A | |
| dc.description.sponsoredbyTubitakEu | N/A | |
| dc.description.studentonlypublication | Yes | |
| dc.description.studentpublication | Yes | |
| dc.description.version | N/A | |
| dc.identifier.WoSQuartile | Q3 | |
| dc.identifier.doi | 10.1111/1440-1681.13224 | |
| dc.identifier.eissn | 1440-1681 | |
| dc.identifier.embargo | N/A | |
| dc.identifier.endpage | 560 | |
| dc.identifier.issn | 0305-1870 | |
| dc.identifier.issue | 4 | |
| dc.identifier.pubmed | 31808190 | |
| dc.identifier.scopus | 2-s2.0-85080836371 | |
| dc.identifier.startpage | 553 | |
| dc.identifier.uri | https://doi.org/10.1111/1440-1681.13224 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14288/13540 | |
| dc.identifier.volume | 47 | |
| dc.identifier.wos | 000508566100001 | |
| dc.keywords | Adenosine | |
| dc.keywords | CPA | |
| dc.keywords | Dopamine | |
| dc.keywords | Morphine | |
| dc.keywords | Noradrenaline | |
| dc.keywords | Nucleus accumbens | |
| dc.language.iso | eng | |
| dc.publisher | Blackwell Publishing | |
| dc.relation.affiliation | Koç University | |
| dc.relation.collection | Koç University Institutional Repository | |
| dc.relation.ispartof | Clinical and Experimental Pharmacology and Physiology | |
| dc.relation.openaccess | N/A | |
| dc.rights | N/A | |
| dc.subject | Pharmacology | |
| dc.title | The role of adenosine A1 receptors in the nucleus accumbens during morphine withdrawal | |
| dc.type | Journal Article | |
| dspace.entity.type | Publication | |
| local.contributor.kuauthor | Topkara, Betilay | |
| relation.isGoalOfPublication | a9786601-9431-4553-9a46-013bb366fb87 | |
| relation.isGoalOfPublication.latestForDiscovery | a9786601-9431-4553-9a46-013bb366fb87 | |
| relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
| relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
| relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
| relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |
